ライフサイエンスコーパス: scleritis

1 tion, known as Th-17, has been implicated in scleritis.

2 n for nonnecrotizing, noninfectious anterior scleritis.

3 tis and other forms of optic neuropathy, and scleritis.

4 to diagnosis and monitoring of patients with scleritis.

5 in the treatment of non-necrotizing anterior scleritis.

6 west medications associated with uveitis and scleritis.

7 and then compared with those with idiopathic scleritis.

8 are, following published recommendations for scleritis.

9 complications of this subset of patient with scleritis.

10 ve medications were studied in patients with scleritis.

11 eptides may be useful in treating uveitis or scleritis.

12 cluded anterior uveitis (80.0%) and anterior scleritis (20.0%).

13 ficantly greater in herpetic than idiopathic scleritis (34.3% vs 11.5%; P<0.001).

14 ectronic health records of 500 patients with scleritis, 35 of whom were diagnosed with herpes virus i

15 Of 500 patients with scleritis, 47 (9.4%) had an underlying infectious cause.

16 statistically significant (P = 0.33) between scleritis (60%) and orbital disease (41%).

17 ilaterality was also more common in herpetic scleritis (80%) than in idiopathic disease (56.7%; P<0.0

18 n a series of 585 patients, 500 patients had scleritis (85.5%) and 85 patients had episcleritis (14.2

19 cal improvement, with 13 (86.6%) achieving a scleritis activity score of zero at 6 months.

20 utcomes were favorable response (decrease in scleritis activity score) and decrease in steroid depend

21 Eighteen patients had anterior scleritis and 12 patients had episcleritis.

22 ients with orbital disease (85% vs. 15% with scleritis and 82% vs. 18% with orbital disease; P = 1.00

23 ectronic health records of 500 patients with scleritis and 85 patients with episcleritis seen at 2 te

24 numbers increased during active uveitis and scleritis and decreased following treatment.

25 t the observed clinical features of herpetic scleritis and describe the clinical differences at prese

26 One patient developed infectious scleritis and diplopia resulting from Tenon capsule scar

27 underrepresented racial group among cases of scleritis and episcleritis (P = .006, P = .001).

28 opulation-based estimate of the incidence of scleritis and episcleritis in a diverse population and h

29 The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) an

30 cted to 129 eyes (1 eye per patient) free of scleritis and hypopyon at the start of AAT, topical cort

31 The association between scleritis and infectious disease may be higher than prev

32 ecular mechanism of scleral diseases such as scleritis and myopia.

33 icacy of rituximab in treating noninfectious scleritis and other ocular inflammatory diseases.

34 tistically significant between patients with scleritis and patients with orbital disease (85% vs. 15%

35 l in treating active, noninfectious anterior scleritis and that gevokizumab is well tolerated.

36 resentation between patients with idiopathic scleritis and those with herpes infection.

37 ment modality for recalcitrant noninfectious scleritis and, in some, can result in long-term durable

38 Twenty patients had scleritis, and 17 patients had orbital disease; 86% achi

39 y tuberculosis, 125 with uveitis, and 6 with scleritis, and 34 healthy control subjects) were screene

40 ith a range of 773-1089 mum in patients with scleritis, and 825 mum (SD +/- 85.57) with a range of 71

41 an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presenta

42 an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presenta

43 loped scleral necrosis, secondary infectious scleritis, and infectious endophthalmitis.

44 nctivitis sicca, cicatricial conjunctivitis, scleritis, and others) mirror other inflammatory ocular

45 eport their involvement in human uveitis and scleritis, and validate our findings in experimental aut

46 iated with these conditions, especially with scleritis, are the connective tissue disorders and syste

47 lled patients with refractory, noninfectious scleritis at 24 weeks, although 7 required reinfusion wi

48 nical records of 104 patients diagnosed with scleritis between 1992 and 2011 at the University Medica

49 Of 217,061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were

50 Herpes viruses account for 7% of all scleritis cases and its diagnosis may be challenging whe

51 antigen staining were noted in the left eye (scleritis, conjunctivitis, and peri-optic neuritis), bra

52 disease characteristics (laterality, type of scleritis, degree of scleral inflammation, ocular compli

53 f inflammation, as measured with a validated scleritis disease grading scale (SGS) and reduction in c

54 ing ICD-9 codes alone to capture uveitis and scleritis/episcleritis diagnoses is not sufficient in th

55 Herpes zoster ophthalmicus and scleritis/episcleritis ICD-9 codes had PPVs of 91% (95%

56 ended to elucidate diagnoses for uveitis and scleritis/episcleritis.

57 hereas 80% of lymphocytes from patients with scleritis failed to induce SOCS1 in response to IL-2.

58 Recurrent PUK with scleritis following alkali burns occurred in 5 male pati

59 ale according to a standardized photographic scleritis grading system by 16 weeks in the study eye co

60 The mild scleritis group had better outcomes in terms of visual i

61 n 18 years who were diagnosed with posterior scleritis in a tertiary referral center.

62 d with seronegative spondyloarthropathy, and scleritis in patients requiring immunomodulation in pati

63 Common features of posterior scleritis include concurrent anterior uveitis, disc swel

64 tors for decrease in vision in patients with scleritis include necrotizing scleritis, posterior scler

65 tors for decrease in vision in patients with scleritis included necrotizing scleritis (odds ratio [OR

66 of 392 patients with noninfectious anterior scleritis included NSAIDs in 144 (36.7%), SAIDs in 29 (7

67 Scleritis is a severe ocular inflammatory disease often

68 Scleritis is associated more often with ocular complicat

69 lications than episcleritis, and necrotizing scleritis is the type of scleritis most often associated

70 take many forms, from orbital pseudotumor to scleritis, keratitis, and retinitis.

71 Mild scleritis/limbitis responsive to topical steroids and or

72 Patients with necrotizing scleritis may respond to IMT, mainly alkylating agents.

73 is, and necrotizing scleritis is the type of scleritis most often associated with ocular complication

74 In general, patients with necrotizing scleritis (n = 15) had a poorer outcome.

75 Patients had refractory scleritis (n=3), orbital granulomas causing optic nerve

76 patients with scleritis included necrotizing scleritis (odds ratio [OR], 6.63; P<0.001), posterior sc

77 nderstanding of the immunopathophysiology of scleritis offers hope for future molecule-specific drug

78 conducted to verify a clinical diagnosis of scleritis or episcleritis.

79 Blood from patients with scleritis or healthy human volunteers was analyzed for S

80 ethal (OR = 17.41, P=0.007), and necrotizing scleritis (OR = 4.73, P = 0.026).

81 (odds ratio [OR], 6.63; P<0.001), posterior scleritis (OR, 2.33; P = 0.042), degree of scleral infla

82 Blacks had the highest incidence of scleritis (P = .004).

83 rred most often in patients with necrotizing scleritis (P<0.0001 for each).

84 Women were overrepresented among scleritis patients (P = .049).

85 patients with scleritis include necrotizing scleritis, posterior scleritis, scleral inflammation of

86 Scleritis preceded systemic disease diagnosis in 38.7% o

87 Most patients with herpetic scleritis presented with acute (85.7%) and unilateral (8

88 edical charts of patients with noninfectious scleritis refractory to conventional immunomodulatory th

89 Twelve patients with noninfectious scleritis refractory to systemic corticosteroid and >/=1

90 in 11 of 36 eyes (31%), and moderate/severe scleritis, requiring systemic immunosuppressive therapy,

91 Scleritis resolved with oral nonsteroidal anti-inflammat

92 tis include necrotizing scleritis, posterior scleritis, scleral inflammation of more than 2+, anterio

93 of 392 patients with noninfectious anterior scleritis seen at 2 tertiary referral centers and studie

94 Patients with active anterior scleritis showed increased thickness of the sclera and p

95 fective expression of SOCS1 in patients with scleritis, taken together with SOCS1-mediated protection

96 nt data regarding the cause and treatment of scleritis that has been identified over the past 36 mont

97 patient subsequently developed noninfectious scleritis that required 3-drug-regimen immunosuppression

98 The follow-up after discontinuation of scleritis treatment was 27.2 +/- 31.8 months.

99 ation was observed in 35.8% of patients with scleritis versus 27.1% of episcleritis patients, includi

100 were more frequent overall in patients with scleritis versus in those with episcleritis (45.0% vs. 1

101 more commonly seen in patients with herpetic scleritis versus patients with idiopathic disease (8.6%

102 The most common type of scleritis was diffuse anterior in 80% (n = 28), followed

103 Necrotizing anterior scleritis was more commonly seen in patients with herpet

104 Scleritis was unilateral in 6 cases and bilateral in 7 c

105 Patients with herpes-associated scleritis were analyzed as a group and then compared wit

106 Nine cases of uveitis and 7 cases of scleritis were treated.

107 ssociated with idiopathic diffuse or nodular scleritis with a high degree of scleral inflammation (>2

108 Patients with idiopathic diffuse or nodular scleritis with a high degree of scleral inflammation may

109 ssociated with idiopathic diffuse or nodular scleritis with a low degree of scleral inflammation (</=

110 Patients with idiopathic diffuse or nodular scleritis with a low degree of scleral inflammation or w

111 ive, noninfectious, non-necrotizing anterior scleritis with a scleral inflammatory grade of +1 to +3

112 h IMT was associated with diffuse or nodular scleritis with associated systemic disease (OR = 1.57, P

113 BRMs was associated with diffuse or nodular scleritis with associated systemic disease (OR = 3.15, P

114 Patients with diffuse or nodular scleritis with associated systemic disease may respond t

115 active, autoimmune, non-necrotizing anterior scleritis with scleral inflammatory grade of >/=1+ in at

116 .001) and with idiopathic diffuse or nodular scleritis without ocular complications (OR = 3.13, P < 0